Pre-clinical and clinical studies demonstrated that D, L-α-diflouromethylornithine (DFMO), a selective ODC inhibitor, exhibited chemopreventive efficacy on CRC [111,112]. This evidence concerns the gene ODC1 and colorectal carcinoma.